Home › Companies › THERAPEUTICSMD INC. › 2024-2025
At THERAPEUTICSMD INC.'s shareholder meeting held December 5, 2024, in the 2024-2025 proxy season, 52 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 153 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — THERAPEUTICSMD INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: THERAPEUTICSMD INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on December 5, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and THERAPEUTICSMD INC.’s Form 8-K, filed December 5, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of December 5, 2024: 6 items on THERAPEUTICSMD INC.’s Form 8-K, filed December 5, 2024: 4 elected · 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore THERAPEUTICSMD INC. in the interactive database Compare manager voting policies
These tallies are THERAPEUTICSMD INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed December 5, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Tommy G. Thompson | 4,599,014 | -- | -- | 259,277 | 1,973,908 | 95% | Elected | — |
| Elect Director: Cooper C. Collins | 4,730,129 | -- | -- | 128,162 | 1,973,908 | 97% | Elected | — |
| Elect Director: Gail K. Naughton, Ph.D. | 4,635,015 | -- | -- | 223,276 | 1,973,908 | 95% | Elected | — |
| Elect Director: Justin Roberts | 4,625,873 | -- | -- | 232,418 | 1,973,908 | 95% | Elected | — |
| 2. On a non-binding, advisory basis, the compensation of the Company's named executive officers for the fiscal year ended December 31, 2023 | 4,609,794 | 218,147 | 30,350 | -- | 1,973,908 | 95% | Approved | — |
| 3. The appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP, an independent registered public accounting firm, as the independent auditor of the Company for the fiscal year ending December 31, 2024 | 6,436,990 | 383,240 | 11,969 | -- | 0 | 94% | Approved | — |
Source: THERAPEUTICSMD INC., Form 8-K, filed with the SEC on December 5, 2024 — read the filing on EDGAR.
Each item below shows how the 52 asset managers that disclosed a THERAPEUTICSMD INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To elect directors to serve until the next annual meeting of stockholders or until their successors are duly elected and qualified: Cooper C. Collins
THERAPEUTICSMD INC.’s own tally for this item (“Elect Director: Cooper C. Collins”): 4,730,129 for, 128,162 withheld, per its Form 8-K filed December 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 : All of the four nominees for the Company's Board of Directors were elected to serve until the Company's next annual meeting of stockholders or until their successors are duly elected and qualified, by the votes set forth in the table below:”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 459,248 for, 35,510 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 382,645 | 0 | 0 | 0 | For |
| Fidelity | 59,098 | 0 | 0 | 1,510 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 34,000 | Withhold |
| Gabelli | 9,500 | 0 | 0 | 0 | For |
| Charles Schwab | 7,060 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 745 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 154 | 0 | 0 | 0 | For |
| Guggenheim | 46 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect directors to serve until the next annual meeting of stockholders or until their successors are duly elected and qualified: Gail K. Naughton, Ph.D.
THERAPEUTICSMD INC.’s own tally for this item (“Elect Director: Gail K. Naughton, Ph.D.”): 4,635,015 for, 223,276 withheld, per its Form 8-K filed December 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 : All of the four nominees for the Company's Board of Directors were elected to serve until the Company's next annual meeting of stockholders or until their successors are duly elected and qualified, by the votes set forth in the table below:”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 460,758 for, 34,000 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 382,645 | 0 | 0 | 0 | For |
| Fidelity | 60,608 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 34,000 | Withhold |
| Gabelli | 9,500 | 0 | 0 | 0 | For |
| Charles Schwab | 7,060 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 745 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 154 | 0 | 0 | 0 | For |
| Guggenheim | 46 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect directors to serve until the next annual meeting of stockholders or until their successors are duly elected and qualified: Justin Roberts
THERAPEUTICSMD INC.’s own tally for this item (“Elect Director: Justin Roberts”): 4,625,873 for, 232,418 withheld, per its Form 8-K filed December 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 : All of the four nominees for the Company's Board of Directors were elected to serve until the Company's next annual meeting of stockholders or until their successors are duly elected and qualified, by the votes set forth in the table below:”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 452,188 for, 42,570 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 382,645 | 0 | 0 | 0 | For |
| Fidelity | 59,098 | 0 | 0 | 1,510 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 34,000 | Withhold |
| Gabelli | 9,500 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 7,060 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 745 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 154 | 0 | 0 | 0 | For |
| Guggenheim | 46 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect directors to serve until the next annual meeting of stockholders or until their successors are duly elected and qualified: Tommy G. Thompson
THERAPEUTICSMD INC.’s own tally for this item (“Elect Director: Tommy G. Thompson”): 4,599,014 for, 259,277 withheld, per its Form 8-K filed December 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 : All of the four nominees for the Company's Board of Directors were elected to serve until the Company's next annual meeting of stockholders or until their successors are duly elected and qualified, by the votes set forth in the table below:”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 459,248 for, 35,510 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 382,645 | 0 | 0 | 0 | For |
| Fidelity | 59,098 | 0 | 0 | 1,510 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 34,000 | Withhold |
| Gabelli | 9,500 | 0 | 0 | 0 | For |
| Charles Schwab | 7,060 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 745 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 154 | 0 | 0 | 0 | For |
| Guggenheim | 46 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2023.
THERAPEUTICSMD INC.’s own tally for this item (“2. On a non-binding, advisory basis, the compensation of the Company's named executive officers for the fiscal year ended December 31, 2023”): 4,609,794 for, 218,147 against — passed, per its Form 8-K filed December 5, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 : The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the fiscal year ended December 31, 2023, by the votes set forth in the table below:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 382,645 | 0 | 0 | 0 | For |
| Fidelity | 60,608 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 34,000 | 0 | 0 | 0 | For |
| Gabelli | 9,500 | 0 | 0 | 0 | For |
| Charles Schwab | 7,060 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 745 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 154 | 0 | 0 | 0 | For |
| Guggenheim | 46 | 0 | 0 | 0 | For |
Fund voting reports, all 8 managers: 494,758 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Rubric Capital Management LP | 1,074,682 | 0 | 0 | 0 | For |
| Clearline Capital LP | 636,622 | 0 | 0 | 0 | For |
| BlackRock | 115,401 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 68,933 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 34,000 | 0 | 0 | 0 | For |
| Northern Trust | 16,403 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 14,660 | 0 | 0 | 0 | For |
| J. Goldman & Co LP | 12,148 | 0 | 0 | 0 | For |
| Clear Harbor Asset Management, LLC | 7,500 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 7,470 | 0 | 0 | 0 | For |
| Charles Schwab | 7,061 | 0 | 0 | 0 | For |
| Vanguard | 4,937 | 0 | 0 | 0 | For |
| Renaissance | 3,837 | 0 | 0 | 0 | For |
| State Street | 3,400 | 0 | 0 | 0 | For |
| Fidelity | 1,689 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 818 | 0 | 0 | 0 | For |
| Resonant Capital Advisors, LLC | 801 | 0 | 0 | 0 | For |
| MONETA GROUP INVESTMENT ADVISORS LLC | 457 | 0 | 0 | 0 | For |
| BANK OF AMERICA NA | 400 | 0 | 0 | 0 | For |
| First Affirmative Financial Network | 330 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 310 | 0 | 0 | 0 | For |
| CAPTRUST FINANCIAL ADVISORS | 271 | 0 | 0 | 0 | For |
| US BANK NATIONAL ASSOCIATION | 246 | 0 | 0 | 0 | For |
| Dorsey & Whitney Trust CO LLC | 200 | 0 | 0 | 0 | For |
| Kovitz Investment Group Partners, LLC | 0 | 200 | 0 | 0 | Against |
Institutional-manager reports, all 46 managers: 2,013,730 for, 200 against. Showing the 25 largest; every one is in the interactive database (link above).
94% Approved · of votes cast
Description as filed by funds: To ratify the appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP, an independent registered public accounting firm, as the independent auditor of the company for the fiscal year ending December 31, 2024.
THERAPEUTICSMD INC.’s own tally for this item (“3. The appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP, an independent registered public accounting firm, as the independent auditor of the Company for the fiscal year ending December 31, 2024”): 6,436,990 for, 383,240 against — passed, per its Form 8-K filed December 5, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 : The Company's stockholders ratified the appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP, an independent registered public accounting firm, as the independent auditor of the Company for the fiscal year ending December 31, 2024, by the votes set forth in the table below:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 494,758 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 382,645 | 0 | 0 | 0 | For |
| Fidelity | 60,608 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 34,000 | 0 | 0 | 0 | For |
| Gabelli | 9,500 | 0 | 0 | 0 | For |
| Charles Schwab | 7,060 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 745 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 154 | 0 | 0 | 0 | For |
| Guggenheim | 46 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 11,532,432 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.32% |
| 2 | Fidelity | 0.53% |
| 3 | BRIDGEWAY FUNDS INC | 0.29% |
| 4 | Gabelli | 0.08% |
| 5 | Charles Schwab | 0.06% |
| 6 | MASTER INVESTMENT PORTFOLIO | <0.01% |
| 7 | CITY NATIONAL ROCHDALE FUNDS | <0.01% |
| 8 | Guggenheim | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Rubric Capital Management LP | 9.32% |
| 2 | Clearline Capital LP | 5.52% |
| 3 | BlackRock | 1.00% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 0.60% |
| 5 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.29% |
| 6 | Northern Trust | 0.14% |
| 7 | AMERIPRISE FINANCIAL INC | 0.13% |
| 8 | J. Goldman & Co LP | 0.11% |
| 9 | Clear Harbor Asset Management, LLC | 0.07% |
| 10 | STIFEL NICOLAUS & CO INC \MO\ | 0.06% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Rubric Capital Management LP | 25.55% | DEF14A |
| Clearline Capital LP | 5.51% | 13G |
| Baselake Partners, LP | 5.26% | 13G |
| Vanguard Group | 3.31% | 13F |
| Morgan Stanley | 1.14% | 13F |
| BlackRock | 1.01% | 13F |
| Geode Capital | 0.97% | 13F |
| Marlan D. Walker | 0.73% | DEF14A |
| Cooper C. Collins | 0.57% | DEF14A |
| Tommy G. Thompson | 0.32% | DEF14A |
Percentages above are of 11,532,432 shares outstanding, as reported by THERAPEUTICSMD INC. on its Form 10-Q dated August 12, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from THERAPEUTICSMD INC.’s 10-Q dated August 12, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
THERAPEUTICSMD INC. proxy season coverage: 2024-2025 (this page) · 2025-2026.
proxyvotesnow.com, “THERAPEUTICSMD (TXMD) 2024 Annual Meeting (2024-2025 season)”, https://proxyvotesnow.com/company/therapeuticsmd-inc/2025 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.